> 1997 Publications
11. Prostate cancer and African-American men.
Moul JW:
Editorial comment to: Oncology, 11(5):611-618, 1997.
12. Prospective evaluation of prostate specific antigen
and prostate specific antigen density in the detection of
carcinoma of the prostate: Ethnic variations.
Moul JW:
Editorial comment to: J Urol, 157:911-912, 1997.
13. Outcome of African American Men Screened for Prostate
Cancer: The Detroit Education and Early Detection Study.
Moul JW:
Editorial comment to: J Urol, 158: 149, 1997.
14. A better definition of advanced prostate cancer
for today’s patients.
Moul JW:
Contemp Urol, pp.15-31. Dec. 1997.
15. Age-specific reference ranges for serum prostate-specific
antigen in black men.
Morgan TO, Jacobsen SJ, McCarthy WF, Moul JW:
Urol. Digest, 3(1):1997.
16. Enzyme/producing gene therapy approach for breast cancer
using a recombinant adenovirus expressing E coli cytosine deaminase.
Li, Z, Shanmugam N, Katayose, D., Huber, B, Srivastava, S, Cowan,
K and Seth, P.
Cancer Gene Therapy 4:113-7,1997
17. Suramin Keratosis: a Unique Skin Eruption in a Patient
Receiving Suramin for Metastatic Prostate Cancer.
Kenner JR, Sperling LC, Waselenko J, Dawson N, Sau P, Moul JW:
J Urol, 158:2245-46, 1997.
18. The influence of ejaculation on serum levels of prostate
specific antigen.
Heidenreich A, Vorreuther R, Neubauer S, Westphal J, Moul JW,
Englemann UH:
Journal of Urology, 157:209-211, 1997.
19. Synchronous bilateral testicular tumour: nonseminomatous
germ cell tumours and contralateral benign tumours.
Heidenreich A, Srivastava S, Engelman, UH:
Scan J Urol Nephrol (Sweden), 389-92, 1997.
20. Prognostic risk factors in low stage testicular germ
cell tumors.
Heidenreich A, Sesterhenn IA, Moul JW:
Cancer, 79:1641-1645, 1997.